ANC-501 in the Treatment of Adults With Major Depressive Disorder
Status:
Not yet recruiting
Trial end date:
2023-03-25
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label Phase 2 study to assess the safety, tolerability,
pharmacokinetics (PK), and activity of ANC-501 oral capsules as adjunctive treatment in
subjects diagnosed with major depressive disorder (MDD)